Albert Bourla, Pfizer CEO (Eric Risberg/AP Images)
January 8, 2024 06:01 PM ESTUpdated January 9, 09:28 AM
R&D
Pharma

Pfiz­er CEO says it's back to ba­sics af­ter painful 2023 for in­vestors: #JPM24

Drew Armstrong

Executive Editor

SAN FRAN­CIS­CO — Pfiz­er CEO Al­bert Bourla said the com­pa­ny has made the ma­jor cost-cut­ting moves re­quired to re­set its busi­ness, and will fo­cus on ex­e­cut­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times